drugset
drugset / Trial / NCT00095940

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

NCT00095940 ↗

Phase 1/2 Completed 52 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

Timeline

Start
2004-10
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 900 mg/m2 Oral

Indications

anaplastic astrocytoma childhood brain stem glioma childhood ependymoma childhood medulloblastoma childhood oligodendroglioma giant cell glioblastoma gliosarcoma